EP1343819A4 - Peptides de fixation de hla-a2.1 et leurs utilisations - Google Patents
Peptides de fixation de hla-a2.1 et leurs utilisationsInfo
- Publication number
- EP1343819A4 EP1343819A4 EP00964938A EP00964938A EP1343819A4 EP 1343819 A4 EP1343819 A4 EP 1343819A4 EP 00964938 A EP00964938 A EP 00964938A EP 00964938 A EP00964938 A EP 00964938A EP 1343819 A4 EP1343819 A4 EP 1343819A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hla
- binding peptides
- peptides
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05016493A EP1619207A3 (fr) | 2000-09-01 | 2000-09-01 | Peptides de fixation de HLA-A2.1 et leurs utilisations |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2000/024102 WO2002020616A1 (fr) | 2000-09-01 | 2000-09-01 | Peptides de fixation de hla-a2.1 et leurs utilisations |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05016493A Division EP1619207A3 (fr) | 2000-09-01 | 2000-09-01 | Peptides de fixation de HLA-A2.1 et leurs utilisations |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1343819A1 EP1343819A1 (fr) | 2003-09-17 |
EP1343819A4 true EP1343819A4 (fr) | 2005-03-23 |
Family
ID=21741736
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00964938A Withdrawn EP1343819A4 (fr) | 2000-09-01 | 2000-09-01 | Peptides de fixation de hla-a2.1 et leurs utilisations |
EP05016493A Withdrawn EP1619207A3 (fr) | 2000-09-01 | 2000-09-01 | Peptides de fixation de HLA-A2.1 et leurs utilisations |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05016493A Withdrawn EP1619207A3 (fr) | 2000-09-01 | 2000-09-01 | Peptides de fixation de HLA-A2.1 et leurs utilisations |
Country Status (5)
Country | Link |
---|---|
EP (2) | EP1343819A4 (fr) |
JP (1) | JP2004517609A (fr) |
AU (1) | AU2000275748A1 (fr) |
CA (1) | CA2420225A1 (fr) |
WO (1) | WO2002020616A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
EP1430076A2 (fr) * | 2001-09-27 | 2004-06-23 | I.D.M. Immuno-Designed Molecules | Polypeptides derives de hsp70 inductible et compositions pharmaceutiques a base de tels polypeptides |
US20060018915A1 (en) * | 2002-04-05 | 2006-01-26 | Glenn Ishioka | Heteroclitic analogs and related methods |
EP2112229A3 (fr) | 2002-11-25 | 2009-12-02 | Sequenom, Inc. | Procédés d'identification du risque du cancer du sein et traitements associés |
EP1903056A3 (fr) * | 2002-12-10 | 2008-05-07 | Idm Pharma, Inc. | Peptides se liant au HLA-A1, -A2, -A3, -A24, -B7 and -B44 et comprenant des épitopes d'antigène associé à une tumeur, et compositions les comprenant |
AU2003296330A1 (en) * | 2002-12-10 | 2004-06-30 | Epimmune Inc. | Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions |
WO2006009838A2 (fr) * | 2004-06-17 | 2006-01-26 | Beckman Coulter, Inc. | Epitopes de mycobacterium tuberculosis et leurs procedes d'utilisation |
EP2391635B1 (fr) | 2009-01-28 | 2017-04-26 | Epimmune Inc. | Polypeptides de liaison de pan-dr et leurs utilisations |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041440A1 (fr) * | 1996-04-26 | 1997-11-06 | Rijksuniversiteit Te Leiden | Procedes de selection et de production d'epitopes peptidiques de lymphocytes t et vaccins contenant lesdits epitopes selectionnes |
WO1998033888A1 (fr) * | 1997-01-31 | 1998-08-06 | Epimmune, Inc. | Cellules a peptides ou a antigenes charges de peptides |
WO2001036452A2 (fr) * | 1999-11-18 | 2001-05-25 | Epimmune Inc. | Analogues heteroclites et procedes associes |
WO2001042270A1 (fr) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Induction de reponses immunes cellulaires a l'antigene carcinoembryonnaire a l'aide des compositions renfermant des peptides et des acides nucleiques |
WO2001041741A1 (fr) * | 1999-12-13 | 2001-06-14 | Epimmune Inc. | Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994020127A1 (fr) * | 1993-03-05 | 1994-09-15 | Cytel Corporation | Peptides se liant a hla-a2.1 et leurs utilisations |
ES2187530T3 (es) * | 1993-08-02 | 2003-06-16 | Scripps Research Inst | Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b. |
US5709995A (en) * | 1994-03-17 | 1998-01-20 | The Scripps Research Institute | Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses |
CA2248667C (fr) * | 1996-03-21 | 2012-06-05 | Epimmune Inc. | Peptides de fixation de hla-a2.1 et leurs utilisations |
IL133912A0 (en) * | 1997-07-10 | 2001-04-30 | Ctl Immunotherapies Corp | A method of inducing ctl response |
JP2003509465A (ja) * | 1999-07-19 | 2003-03-11 | エピミューン, インコーポレイテッド | ペプチドおよび核酸組成物を使用する、c型肝炎ウイルスに対する細胞性免疫応答の誘導 |
AT408721B (de) * | 1999-10-01 | 2002-02-25 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung enthaltend ein antigen |
-
2000
- 2000-09-01 AU AU2000275748A patent/AU2000275748A1/en not_active Abandoned
- 2000-09-01 WO PCT/US2000/024102 patent/WO2002020616A1/fr not_active Application Discontinuation
- 2000-09-01 CA CA002420225A patent/CA2420225A1/fr not_active Abandoned
- 2000-09-01 JP JP2002525235A patent/JP2004517609A/ja active Pending
- 2000-09-01 EP EP00964938A patent/EP1343819A4/fr not_active Withdrawn
- 2000-09-01 EP EP05016493A patent/EP1619207A3/fr not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997041440A1 (fr) * | 1996-04-26 | 1997-11-06 | Rijksuniversiteit Te Leiden | Procedes de selection et de production d'epitopes peptidiques de lymphocytes t et vaccins contenant lesdits epitopes selectionnes |
WO1998033888A1 (fr) * | 1997-01-31 | 1998-08-06 | Epimmune, Inc. | Cellules a peptides ou a antigenes charges de peptides |
WO2001036452A2 (fr) * | 1999-11-18 | 2001-05-25 | Epimmune Inc. | Analogues heteroclites et procedes associes |
WO2001042270A1 (fr) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | Induction de reponses immunes cellulaires a l'antigene carcinoembryonnaire a l'aide des compositions renfermant des peptides et des acides nucleiques |
WO2001041741A1 (fr) * | 1999-12-13 | 2001-06-14 | Epimmune Inc. | Compositions de vaccins et peptides d'antigene associes a une tumeur de hla-a2 de classe i |
Non-Patent Citations (5)
Title |
---|
ALTERS S E ET AL: "DENDRITIC CELLS PULSED WITH CEA PEPTIDE INDUCE CEA-SPECIFIC CTL WITH RESTRICTED TCR REPERTOIRE", JOURNAL OF IMMUNOTHERAPY, RAVEN PRESS, NEW YORK, US, vol. 21, no. 1, January 1998 (1998-01-01), pages 17 - 26, XP001061479, ISSN: 1524-9557 * |
FALK K ET AL: "ALLELE-SPECIFIC MOTIFS REVEALED BY SEQUENCING OF SELF-PEPTIDES ELUTED FROM MHC MOLECULES", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 351, no. 6324, 23 May 1991 (1991-05-23), pages 290 - 296, XP000310533, ISSN: 0028-0836 * |
KAWASHIMA I ET AL: "THE MULTI-EPITOPE APPROACH FOR IMMUNOTHERAPY FOR CANCER: IDENTIFICATION OF SEVERAL CTL EPITOPES FROM VARIOUS TUMOR-ASSOCIATED ANTIGENS EXPRESSED ON SOLID EPITHELIAL TUMORS", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 59, no. 1, January 1998 (1998-01-01), pages 1 - 14, XP001012509, ISSN: 0198-8859 * |
See also references of WO0220616A1 * |
WIZEL BENJAMIN ET AL: "Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses", JOURNAL OF CLINICAL INVESTIGATION, vol. 102, no. 5, 1 September 1998 (1998-09-01), pages 1062 - 1071, XP002285521, ISSN: 0021-9738 * |
Also Published As
Publication number | Publication date |
---|---|
CA2420225A1 (fr) | 2002-03-14 |
WO2002020616A1 (fr) | 2002-03-14 |
AU2000275748A1 (en) | 2002-03-22 |
EP1619207A3 (fr) | 2006-02-08 |
EP1343819A1 (fr) | 2003-09-17 |
JP2004517609A (ja) | 2004-06-17 |
EP1619207A2 (fr) | 2006-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI317737B (en) | Membrane penetrating peptides and uses thereof | |
GB0014870D0 (en) | Peptides | |
GB2362604B (en) | Book cover and book binding system using the book cover | |
EP1263775A4 (fr) | Peptides de liaison hla et utilisations de ces derniers | |
GB9806806D0 (en) | Peptides and uses thereof | |
IL153539A0 (en) | Protein complexes and methods for the preparation thereof | |
EP1343819A4 (fr) | Peptides de fixation de hla-a2.1 et leurs utilisations | |
IL131707A0 (en) | Acetylcholinesterase-derived peptides and uses thereof | |
GB0029777D0 (en) | Peptides | |
GB0026134D0 (en) | Peptides and their use | |
GB0015761D0 (en) | Polypeptide | |
GB0001825D0 (en) | Peptides | |
EP1313505A4 (fr) | Peptides de fixation de hla et leurs utilisations | |
GB0121215D0 (en) | Polypeptide | |
AU6534301A (en) | Phosphorylated polypeptides and uses related thereto | |
EP1071434A4 (fr) | Facteurs de liaison cnre et utilisations correspondantes | |
GB0007263D0 (en) | Peptides | |
AU5995701A (en) | Synthetic peptides and uses therefore | |
GB0013239D0 (en) | Polypeptide | |
EP1300416A4 (fr) | Peptide d'augmentation de la memoire et ses applications | |
AU4726901A (en) | Novel human proteins and polynucleotides encoding the same | |
AU8557801A (en) | Modified proteins, isolated novel peptides, and uses thereof | |
MXPA03000981A (es) | Polipeptidos de integrina de alta afinidad y uso de los mismos. | |
GB0026135D0 (en) | Peptides and their use | |
GB0018148D0 (en) | Peptides and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030219 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 12N 9/90 B Ipc: 7C 07K 14/18 B Ipc: 7C 07K 14/16 B Ipc: 7C 07K 14/11 B Ipc: 7C 07K 14/08 B Ipc: 7C 07K 14/03 B Ipc: 7C 07K 14/02 B Ipc: 7A 61K 39/00 B Ipc: 7C 07H 21/04 B Ipc: 7C 07K 16/00 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050202 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060404 |